Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

Cancer Clinical Trial

Official title:

Phase I, Sequential Dose Escalation Clinical Study to Investigate the Safety, Tolerability and Pharmacokinetics of in Patients With Advanced Solid Tumor

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02151357
• Other study ID #: DCBCI 0901 101
• Status: Terminated
• Phase: Phase 1
• First received: May 27, 2014
• Last updated: October 4, 2017
• Start date: August 19, 2014
• Est. completion date: October 31, 2016

Study information

• Verified date: October 2017
• Source: Standard Chem. & Pharm. Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

• Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor

• Pharmacokinetic parameters will be calculated for DCBCI0901, if data permit.

• Anti tumor activity: The efficacy endpoint will be the overall response rate (ORR) defined as the proportion of patients who continuously receive treatment after Cycle 1 with a best overall response of complete response (CR) or partial response (PR).

Description:

This is a Phase I, open label, first in human study designed to evaluate the safety, tolerability and PK of escalating doses of DCBCI0901 in patients with advanced solid tumors. Each treatment cycle will be 28 days in duration with no gap between cycles. During each cycle, DCBCI0901 will be administered slowly as a 30 minute intravenous (IV) infusion (use of infusion pump preferred) once daily (QD) in the first 5 day dosing period (Days 1 to 5), which will be followed by 9 days of recovery and observation (Days 6 14). DCBCI0901 will be administered intravenously QD in a second 5 day dosing period (Days 15 through 19), followed again by 9 days of recovery and observation (Days 20 through 28).

Patients may continue to receive treatment in 28 day cycles after completion of Cycle 1. To qualify for continued treatment beyond Cycle 1, all of the following criteria must be fulfilled:

• The patient is willing to receive further treatment

• Toxicity induced by the IP is not considered to be unbearable as judged by the Investigator

• The patient does not have PD as defined by Response Evaluation Criteria in Solid Tumors

• The patient satisfies the criteria for dosing

• The patient does not meet any of the criteria for withdrawal

After the first cycle, CT/MRI assessment will be performed once every 8 weeks (2 cycles) for efficacy evaluation, or per Investigator judgment. After the first year of treatment, the Investigator will assess the patient using CT/MRI based on his/her discretion.

Safety data will be evaluated according to normal practice.

Upon discontinuation of study treatment (if applicable), assessments for the Early termination visit (if discontinuation occurs in Cycle 1) or End of Treatment visit (if discontinuation occurs in Cycle 2 or onwards) should occur within 3 days of discontinuation. Assessments for the Follow up visit (10 days [±1 day] after the last dose of IP) and End of Study (EOS) visit (30 days [±3 days] after the last dose of IP)

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 17
• Est. completion date: October 31, 2016
• Est. primary completion date: June 24, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Adult male or female patients, age at consent =20 years.

2. Patients with pathologically or cytologically confirmed advanced solid tumor(s), failed to respond to standard therapy.

3. Measurable or non measurable disease on imaging by RECIST v1.1.

4. ECOG PS of 0 and 1.

5. Any acute or chronic clinically significant adverse effects of prior chemotherapy have resolved to =Grade 1 as determined by the CTCAE v4.0 criteria.

6. Life expectancy =12 weeks.

7. No prior cytotoxic chemotherapy, radiation therapy, or immunosuppressive therapy within 4 weeks of starting study treatment.

8. Have not participated in any other investigational trials within 28 days before commencing the study treatment.

9. Eligible organ function

10. Patients with primary liver cancer or hepatic metastasis are eligible to enroll,

11. No active infections or unstable angina, or myocardial infarction within 6 months or coexisting medical problems of sufficient severity to limit compliance in the study.

12. No known concomitant genetic or acquired immunosuppressive diseases

13. No history of alcoholism, drug addiction or psychotic disorders.

14. Negative urine ß human chorionic gonadotropin test in women of childbearing potential at Screening.

15. Patients who agree that they or their partner(s), if WOCBP, will practice contraception during the study period

16. If there is a history of brain metastases or spinal cord compression treated with radiation and/or surgery, the therapy must have occurred at least 3 months prior to enrollment and the metastatic disease must have been stable since completion.

17. Patients who are fully informed about the content of the study by the Investigator using the specified written consent form

Exclusion Criteria:

1. Uncontrolled systemic infection at Screening, including patients who are positive and at risk

2. Severe or poorly controlled systemic illnesses that may affect the conduct or results of the study.

3. Presence of =Grade 2 non hematological AEs at Screening for which a causal relationship with prior therapies cannot be ruled out

4. Long QT syndrome,

5. Symptoms of peripheral neuropathy.

6. Concomitant treatment with, or anticipated use of, pharmaceutical, non pharmaceutical agents which are known potent inhibitors for Cytochrome P450

7. Patients on traditional Chinese medicine (TCM) or plan to take TCM.

8. Women who are nursing or pregnant during the study period.

9. Patients who have a history of hypersensitivity to mTOR inhibitors or any of the ingredients.

10. Patients who cannot communicate reliably with the Investigator.

11. Patients who are unlikely to cooperate with the requirements of the study.

12. Other cases judged by the Investigator to be ineligible for participation in the study.

Related Conditions & MeSH terms

• Cancer

Intervention

Drug:
• DCBCI0901
DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20

Locations

Country	Name	City	State
Taiwan	National Cheng Kung University Hospital	Tainan
Taiwan	National Taiwan University Hospital	Taipei
Taiwan	Taipei Veterans General Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Standard Chem. & Pharm. Co., Ltd.

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	•Anti tumor activity	The efficacy endpoint will be the overall response rate (ORR) defined as the proportion of patients who continuously receive treatment after Cycle 1 with a best overall response of complete response (CR) or partial response (PR).	one year
Primary	• Investigate the safety and tolerability of multiple DCBCI0901 infusions in patients with advanced solid tumor	AE and SAE, physical examination, vital signs, weight, clinical laboratory examinations (hematology, blood chemistry, blood coagulation, and urinalysis), pulmonary function tests, pulse oximetry, and ECGs. Adverse events and SAEs will be collected from the time of informed consent, throughout the study, until the EOS visit or up to 1 year of treatment.	one year
Secondary	• Pharmacokinetic parameters as described below will be calculated for DCBCI0901, if data permit.	Pharmacokinetic parameters will be determined from DCBCI0901 plasma concentrations using noncompartmental methods. DCBCI0901 PK parameters to be calculated (if adequate data are available for estimation) will include Cmax, time to Cmax (tmax), applicable AUC parameters such as AUC from time zero to the last quantifiable time point (AUC(0 last)), AUC from time zero to infinity (AUC(0 inf)), and/or AUC over the dosing interval tau (AUC(0 tau)), terminal half life (t1/2), systemic clearance (CL), steady state volume of distribution and volume of distribution in the terminal phase (Vss and Vz, respectively), and multiple/single dose accumulation parameters for Cmax and AUC (RCmax and RAUC).	28